Alnylam Pharmaceuticals, Inc. ALNY

What this company does

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company that develops therapeutics based on ribonucleic acid interference, or RNAi. It currently has six marketed products, including two commercialized by collaborators, and more than 20 clinical programs, including several in late-stage development. As of December 31, 2025, it employed approximately 2,500 full-time employees, of whom approximately 1,945 were employed in the U.S. and approximately 555 were employed outside of the U.S. AMVUTTRA is approved for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy in the United States, for hATTR amyloidosis with stage 1 or stage 2 polyneuropathy in the European Union and the United Kingdom, for transthyretin-type familial amyloidosis with polyneuropathy in Japan, and in multiple additional countries. Alnylam Pharmaceuticals, Inc. is a Delaware corporation that was formed in May 2003.

Written from the business description in ALNYLAM PHARMACEUTICALS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 12 February 2026. Every sentence was checked against that document before publication.